本文转载自:投中网,作者:陈美。猎云网已获授权。如果说,前几年“敲钟上市”是创新药企业最大的梦想,那么“被并购”如今也成了Biotech公司的一条现实出路。近日,一起并购交易引发关注。中国生物制药公告披露,于2025年7月15日(交易时段后),其通过旗下买方与卖方、礼新医药及YingQinZang订立买卖协议,全资收购礼新医药。公告显示,本次交易对价不超过9.51亿美元(约68亿元人民币)。剔除...
Source Link本文转载自:投中网,作者:陈美。猎云网已获授权。如果说,前几年“敲钟上市”是创新药企业最大的梦想,那么“被并购”如今也成了Biotech公司的一条现实出路。近日,一起并购交易引发关注。中国生物制药公告披露,于2025年7月15日(交易时段后),其通过旗下买方与卖方、礼新医药及YingQinZang订立买卖协议,全资收购礼新医药。公告显示,本次交易对价不超过9.51亿美元(约68亿元人民币)。剔除...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.